

Asthma

A study of a new medicine for asthma and cough: GDC-6599, a TRPA1 inhibitor

Trial Status Completed	Trial Runs In 1 Countries	Trial Identifier 2021-002464-48 GA43010
----------------------------------	-------------------------------------	---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This clinical trial was done to study a new medicine, “GDC-6599,” for the treatment of people with asthma. This study was done to look at side effects at different doses and learn about whether this medicine was safe and could be tolerated by people. Researchers also wanted to learn about the effect of food on this medicine and whether it had any effect on the cell structure it was targeting. This was a phase 1, placebo-controlled, randomized, double-blind, dose-escalation study that was conducted at one study center in the Netherlands.

Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland) Sponsor	Phase 1 Phase
--	-------------------------

2021-002464-48 GA43010
Trial Identifiers

Eligibility Criteria:

Gender All	Age 18 to 75 years	Healthy Volunteers Yes
----------------------	------------------------------	----------------------------------

GDC-6599, a new TRPA1 inhibitor, is under development for the treatment of asthma and cough. This trial was conducted at a single study center in the Netherlands, involving 81 healthy volunteers. Some were given GDC-6599. Others were given a fake medicine (placebo) that did not have any real medicine in it. Results from the study showed no serious side effects. Thirteen people had non-serious side effects that doctors thought were related to the treatments.